Bexirestrant
Bexirestrant is a selective [estrogen receptor degrader] which is being evaluated for the treatment of breast cancer. This orally bioavailable compound has demonstrated potent activity against both wild-type and mutant forms of the estrogen receptor, addressing a critical need in overcoming resistance to current endocrine therapies.
It is structurally characterized by an E-alkene linked to an azetidine core.